How to Get a GLP-1 Prescription Online: Step-by-Step
This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency.
Getting a GLP-1 prescription is not as simple as filling out a form and receiving medication. It requires a real clinical evaluation by a licensed provider who reviews your health history and decides whether the medication is medically appropriate for you.
This section explains the main routes to a prescription, what that evaluation should cover, and what to check before you choose a provider. Transformation Health is an independent guide: it does not prescribe, run a program, or sell medication.
What’s in This Section
This section covers what to know before and during the prescription process. For more detail on specific topics, see:
- How the Telehealth Process Works – How the telehealth process typically works at most programs, from the health history form to the provider’s decision, labs, shipping, and refills, and what to ask at each step
- Which GLP-1 Program Is Right for You? – How the main program types differ (brand-name through insurance, manufacturer self-pay, cash-pay telehealth with brand-name or compounded medication, and in-person clinics), and what a licensed provider weighs when choosing a medication
- Choosing a Provider – Primary care provider vs. telehealth vs. specialist, what to look for in a provider, and how to find care in healthcare access deserts
- Getting Started Without Insurance – What drives cash-pay costs, patient assistance programs, label eligibility criteria, and options if you do not have coverage
Why the Evaluation Matters
GLP-1 medications like semaglutide and tirzepatide act on appetite, digestion, and blood sugar regulation. They are not appropriate for everyone. A prescriber needs to know your full health history, current medications, and any contraindications before prescribing.
The evaluation is not a barrier. It is a safeguard. If you receive a prescription, it should be because a licensed provider believes the expected benefit outweighs the risks for your specific situation.
GLP-1 medication steps for approval
There is no single number, because a licensed provider decides case by case. What the FDA labels do define is who the medications are approved for. For weight management, Wegovy is indicated for adults with obesity (the injection also for children 12 and older with obesity), and adults with overweight and at least one weight-related condition[2]. Zepbound is indicated for adults with obesity, or adults with overweight and at least one weight-related condition[3]. Both are used with a reduced-calorie diet and increased physical activity.
For adults, NIDDK describes this as [1]:
- A BMI of 30 or higher, or
- A BMI of 27 or higher with weight-related health problems, such as high blood pressure or type 2 diabetes
BMI alone does not decide it. A provider also looks at your medical history, your medications, and any conditions that make a GLP-1 medication inappropriate. For national data on how common obesity is, see obesity prevalence in the United States.
Routes to a GLP-1 Prescription
Most people get a GLP-1 prescription through one of four routes (the table splits telehealth into brand-name and compounded programs). Each has trade-offs in cost, speed, and which medications are available.
| Route | Who prescribes | Medication | What to check |
|---|---|---|---|
| Insurance, through your primary care provider or a specialist | Your own primary care provider, or an obesity medicine or endocrinology specialist | Brand-name, if your plan covers it | Whether your plan covers GLP-1s for weight management, prior authorization rules, and your copay |
| Telehealth, brand-name | A licensed prescriber working with the telehealth program | Brand-name, filled at a pharmacy or through a manufacturer self-pay option | Visit and membership fees on top of the medication, and whether the prescriber is licensed in your state |
| Telehealth, compounded | A licensed prescriber working with the telehealth program | Compounded semaglutide or tirzepatide (not FDA-approved) | Which pharmacy prepares it, its license type, batch testing, and the total cost at your likely dose |
| Manufacturer self-pay | Any licensed prescriber you see | Brand-name, through the manufacturer’s self-pay pharmacy option | Which doses the offer covers, and that self-pay costs generally do not count toward insurance |
| In-person clinic | A prescriber at a local weight management or medical clinic | Brand-name or compounded, depending on the clinic | Visit fees, follow-up schedule, and where the medication comes from |
Insurance through your own provider. If your plan covers GLP-1 medications for weight management, your primary care provider or a specialist can prescribe, and your plan may require prior authorization. Coverage varies widely by plan, and Medicare Part D generally excludes drugs used only for weight loss. See GLP-1 prior authorization and what insurance covers.
Telehealth programs. Telehealth programs connect you with a licensed prescriber online. Some prescribe brand-name medications; others prescribe compounded versions prepared by a compounding pharmacy. Programs differ in how they review your history, whether they require labs or a video visit, and what their fees include.
Manufacturer self-pay. Both the semaglutide and tirzepatide manufacturers list self-pay options for brand-name medication when you have a prescription. Terms and prices change, so check the manufacturer’s current page. See GLP-1 savings programs for the current terms we have checked.
In-person clinics. Local weight management clinics and medical practices can evaluate you in person and prescribe. Some also offer nutrition support or regular weigh-ins. Ask what each visit costs and where the medication is filled.
Prices vary by program and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms.
Transformation Health does not accept payment from providers. How we make money.
How the process should work
Step 1: Health history
You share your medical history, medications, and goals, through a visit or an online form.
Step 2: Provider review
A licensed provider reviews your information and decides whether a GLP-1 medication is clinically appropriate.
Step 3: Pharmacy
If a prescription is written, a licensed pharmacy fills it, and the provider follows up during treatment.
Step 1: Share Your Health History
Whether you see your own provider or use a telehealth program, the prescriber needs enough information to make a clinical decision. Expect questions about:
Your health profile:
- Age, height, weight, and BMI
- Current medical conditions (thyroid disease, diabetes, heart disease, cancer history, pancreatitis, gallbladder disease, kidney disease)
- Family medical history, including thyroid cancer
- Previous weight loss attempts
Your medications:
- All prescription medications, including doses
- Over-the-counter medications and supplements
- Any allergies or adverse drug reactions
Your goals and preferences:
- What you hope treatment will help with
- Whether you prefer an injection or a tablet
- Any specific health concerns or questions
Telehealth programs often also ask for a photo ID to verify identity. Before you share health information with any program, read its privacy policy and check who can see your answers.
Step 2: Provider Clinical Review
A licensed provider should review your history before anything is prescribed. A health history form that leads to a prescription with no provider involvement is a red flag.
What the provider should evaluate:
- Your BMI and whether the medication’s label indication fits your situation
- Your health history, focusing on contraindications
- Your current medications and possible interactions
- Whether a GLP-1 medication is clinically appropriate for you
- Which medication (if any) and what starting dose fit
- What monitoring and follow-up you will need
The provider’s possible decisions:
- Write a prescription if a GLP-1 medication is medically appropriate
- Decline if it is not appropriate for your health profile
- Ask for more information, such as labs or records
Ask each program up front what you pay if the provider declines, and what a visit or membership costs either way.
Step 3: Filling the Prescription
Where the prescription goes depends on the route:
- A brand-name prescription can be filled at a retail or mail-order pharmacy, or through a manufacturer’s self-pay pharmacy option
- A compounded prescription goes to a compounding pharmacy (a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility) that prepares it
- Injectable GLP-1 medications need refrigeration, so mail-order shipments should arrive in temperature-controlled packaging
- You should receive dosing instructions and a way to reach the prescriber with questions
Timelines vary by program, insurance approval, and pharmacy. Ask for the program’s current timeline in writing. For more on shipping, see how GLP-1 medication shipping works.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedWhat the Provider Evaluates (The Clinical Side)
Understanding what a provider looks at helps explain why this should not be a rubber-stamp process.
Eligibility criteria [1][2][3]: The labels for Wegovy and Zepbound cover adults with obesity, or adults with overweight and at least one weight-related condition. NIDDK describes this as a BMI of 30 or higher, or 27 or higher with weight-related health problems. The provider decides whether the indication fits you.
Contraindications [2][3]: Both labels carry a boxed warning about the risk of thyroid C-cell tumors, and both say the medication should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, or with a known serious hypersensitivity to the drug. The labels also list warnings for acute pancreatitis, gallbladder disease, low blood sugar (especially with insulin or sulfonylureas), kidney injury from dehydration, severe gastrointestinal reactions, and diabetic retinopathy complications in people with type 2 diabetes. A provider weighs these against your history.
Medication interactions [2][3]: GLP-1 medications slow stomach emptying, which can affect how some oral medications are absorbed. If you take insulin or a sulfonylurea, the labels note a higher risk of low blood sugar, and your provider may adjust those doses.
Overall health picture: A provider considers your full situation. Someone with well-controlled diabetes may be a good candidate. Someone in active cancer treatment may not be. Someone with kidney disease may need closer monitoring. These are individual clinical decisions made by a licensed provider, not automated rules.
Realistic expectations: A provider may also talk with you about what the medication can and cannot do. The labels approve these medications for use with a reduced-calorie diet and increased physical activity.
Differences Between Telehealth and In-Person Evaluation
Many people wonder whether a telehealth evaluation is as thorough as an in-person visit. For many people the decision rests on health history, current medications, BMI, and goals, which can be shared remotely. A good telehealth program asks detailed questions and follows up when something is unclear.
If a provider decides an in-person exam or lab work is needed for your situation, they should tell you. Requirements for video visits and other telehealth rules vary by state and by program. Ask whether the program requires a live video or phone visit where you live, and whether the prescriber is licensed in your state. You can look up a license on your state’s medical, nursing, or physician assistant board website.
What to check before using compounded GLP-1 medication
What are compounded medications?
Compounded medications are prepared by licensed compounding pharmacies according to a prescriber’s order. Some telehealth programs and clinics prescribe compounded semaglutide or tirzepatide instead of a brand-name product.
Compounded products are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed[4].
This matters. It means [4]:
- Compounded products have not been evaluated by the FDA for safety, effectiveness, or quality
- Formulation, purity, and potency may differ between pharmacies and from brand-name products
- Quality depends on the pharmacy’s practices and on state or FDA oversight
- You should discuss compounded vs. brand-name options with your provider
Why do people consider compounded medication?
The main reason people give is cost. Prices vary by program and dose, so compare the total cost: medication at your likely dose, dose increases, visits, labs, shipping, membership fees, and cancellation terms. The trade-off is accepting a product the FDA has not approved. That is a decision to make with a licensed provider.
What to ask about the pharmacy:
- Which pharmacy prepares the medication, and is it a 503A pharmacy or a 503B outsourcing facility?
- Where can you look up its state license or FDA registration?
- Does it test each batch for potency, purity, and sterility, and can you see a certificate of analysis?
- What form of the active ingredient does it use? The FDA has raised concerns about salt forms such as semaglutide sodium and semaglutide acetate[4].
For a full checklist, see how to choose a compounded GLP-1 provider.
Who Is Responsible for What
This is important to understand:
The prescriber (your provider):
- Reviews your health history
- Makes all clinical decisions about whether medication is appropriate
- Writes the prescription if clinically indicated
- Decides the specific medication, dose, and monitoring plan
- Is legally and clinically responsible for the prescription
The program or practice (telehealth company, clinic, or medical office):
- Runs scheduling, messaging, and billing
- Sets its own fees, membership terms, and cancellation policy
- Decides which pharmacies it works with
The pharmacy:
- Receives and fills the prescription
- For compounded medications, prepares the medication and is responsible for its quality and sterility
- Packages and ships the medication, if it offers mail order
Transformation Health:
- Publishes this guide and, at relaunch, a free custom report that lists providers that fit your answers
- Does not prescribe, provide medical care, sell or ship medication, or take part in your treatment
- You choose and contact any provider directly
What a proper weight loss program should include
Once a provider writes a prescription, good care continues well past the first fill. Whatever route you choose, look for:
At the start:
- Clear dosing and injection or tablet instructions
- Information on common side effects and when to seek help
- A way to reach the prescriber with questions
During dose increases:
- A gradual dose schedule. The Wegovy injection and Zepbound labels both start at a low dose and increase it in steps at least 4 weeks apart, to reduce gastrointestinal side effects[2][3]
- Check-ins with a licensed provider about how you are tolerating the medication
- Lab work when the provider orders it
- Support with nutrition and activity, since the medications are approved for use alongside both
Over the longer term:
- Regular follow-up on progress and side effects
- Dose adjustments when needed
- A plan for what happens if you need to pause or stop
Ask each program what it includes and what is billed separately, so you can compare the total cost.
Eligibility Summary
These are the adult thresholds NIDDK describes for weight management medications[1], which match the adult weight-management indications on the Wegovy and Zepbound labels[2][3]. Meeting them does not mean a prescription is appropriate. A licensed provider evaluates your complete health profile and makes the decision.
Choosing Your Medication
If a provider decides a GLP-1 medication is appropriate, the next question is which one and in what form. The provider makes the final recommendation based on your health profile, but you can share your preferences.
Semaglutide (brand-name Wegovy, injection or tablet) FDA-approved for chronic weight management, and to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight[2].
Tirzepatide (brand-name Zepbound, injection) Acts on both GLP-1 and GIP receptors. FDA-approved for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity[3].
Compounded semaglutide or tirzepatide Prescribed by some telehealth programs and clinics. Not FDA-approved, and not the same as the brand-name products. Trial results for Wegovy and Zepbound do not apply to compounded versions.
The most common side effects on both labels are gastrointestinal, including nausea, diarrhea, vomiting, constipation, and abdominal pain[2][3]. For trial results, label safety information, and a side-by-side comparison, see the medication comparison page. Prices vary by program and dose.
Frequently Asked Questions
Will my insurance cover this? It depends on your plan. Some commercial plans cover GLP-1 medications for weight management, often with prior authorization; many do not. Medicare Part D generally excludes drugs used only for weight loss, and Medicaid coverage varies by state. Call your plan to check, and see what insurance covers.
What if I have a contraindication? If you have a condition that makes a GLP-1 medication inappropriate, the provider should decline to prescribe it and may discuss other approaches for your situation.
What are the side effects? The most common side effects in the labels are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain, among others[2][3]. Both labels also carry a boxed warning about thyroid C-cell tumors and list serious warnings including pancreatitis, gallbladder disease, and kidney injury. Ask your provider how side effects will be monitored and managed.
How long do I stay on the medication? That is a decision you and your provider make together. The labels describe these as medications to reduce weight and maintain the reduction long term[2][3]. Talk with your provider about how long treatment is expected to last and what happens if you stop.
Will I regain the weight if I stop? Many people do. In the SURMOUNT-4 trial of tirzepatide, participants who lost weight over a 36-week lead-in and were then switched to placebo regained an average of 14.0% of their body weight over the next 52 weeks, while those who stayed on tirzepatide lost a further 5.5% on average[5]. Results vary. Trial results describe study participants and are not a prediction for any individual, and they apply to the FDA-approved product studied, not to compounded versions.
Information About Compounded Medications
Compounded medications are prepared by licensed compounding pharmacies and are not FDA-approved. According to the FDA, the agency does not review compounded drugs for safety, effectiveness, or quality before they are marketed[4].
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as brand-name products such as Wegovy or Zepbound. They may differ in formulation, purity, and potency.
Regulatory status can change. On December 19, 2024, the FDA reissued its determination that the tirzepatide injection shortage was resolved, and on February 21, 2025, it determined that the semaglutide injection shortage was resolved; the FDA’s page on these decisions was most recently updated April 1, 2026[6]. Check that page for the current statement.
If you have concerns or prefer a brand-name product, discuss this with your provider.
Important disclosures
This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication. A licensed provider decides whether a prescription is appropriate. Transformation Health does not accept payment from providers. How we make money.
Results vary. Trial results describe study participants and are not a prediction for any individual.
Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.
Citations
[1] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Prescription Medications to Treat Overweight & Obesity.” https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity (Accessed 2026-10-16.)
[2] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, Prescribing Information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[3] U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection, Prescribing Information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[4] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16.)
[5] Aronne LJ, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA. 2024;331(1):38-48. PMID 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/
[6] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16.)